Approval · Notice of Compliance 33823 · 2024
ZESTORETIC: Notice of Compliance 33823
Issued August 16, 2024
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 33823
- Date
- August 16, 2024
- Company
- Searchlight Pharma Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Addition of a manufacturing site and/or manufacturer involving production of the drug substance (Lupin for Lisinopril Drug Substance only. Addition of a drug product manufacturing site and/or manufacturer involving production (Addition of ROVI Pharma Industrial Services S.A.). Addition of a primary container closure system (Addition of Blister pack of 30 Tablets for ROVI Pharma Industrial Services S.A. Only)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ZESTORETIC | Not yet assigned | — |
Medicinal ingredients
- HYDROCHLOROTHIAZIDE 12.5 MG per TAB
- LISINOPRIL 10 MG per TAB
- LISINOPRIL 20 MG per TAB
- HYDROCHLOROTHIAZIDE 25 MG per TAB